FDA nano-teams with academia
This article was originally published in The Tan Sheet
FDA collaborates with the Alliance for NanoHealth to hasten development of novel medical products using nanotechnology. The FDA/ANH Nanotechnology Initiative aims to expand understanding of how nanoparticles affect biologic systems and develop processes to potentially mitigate nano-related risks, all of which will be placed in the public domain. FDA March 10 said the collaboration is part of its Critical Path initiative for biomarker validation, better clinical trial design and new manufacturing methods (1"The Tan Sheet" Oct. 3, 2005, p. 7)
You may also be interested in...
The appointment of National Cancer Institute Director Andrew von Eschenbach to FDA acting commissioner is likely to revitalize the agency's stalled Critical Path initiative
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.